Samlyn Capital, LLC Corvus Pharmaceuticals, Inc. Transaction History
Samlyn Capital, LLC
- $6.07 Billion
- Q1 2025
A detailed history of Samlyn Capital, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Samlyn Capital, LLC holds 4,065,935 shares of CRVS stock, worth $18.3 Million. This represents 0.21% of its overall portfolio holdings.
Number of Shares
4,065,935
Previous 6,667,105
39.01%
Holding current value
$18.3 Million
Previous $34.7 Million
62.71%
% of portfolio
0.21%
Previous 0.56%
Shares
8 transactions
Others Institutions Holding CRVS
# of Institutions
107Shares Held
37.2MCall Options Held
1.37MPut Options Held
338K-
Orbimed Advisors LLC San Diego, CA6.94MShares$31.2 Million0.69% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$14.7 Million10.31% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$12.5 Million0.02% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$12.1 Million0.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.49MShares$11.2 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $209M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...